Neuropacs Corp.'s MRI AI software earns FDA De Novo classification to assist in Parkinsonian syndrome diagnosis.
Key Details
- 1Neuropacs Corp. developed an AI-enabled MRI software targeting neurodegenerative disease evaluation.
- 2The tool differentiates between Parkinson’s disease, atypical parkinsonism, multiple system atrophy Parkinsonian variant, and progressive supranuclear palsy.
- 3FDA has granted the product De Novo classification, indicating novel technology.
- 4The software quantifies MRI data and aids in more accurate clinical decision-making.
Why It Matters
FDA De Novo clearance validates the clinical utility of this MRI-based AI tool, potentially supporting radiologists in systematizing diagnosis of challenging neurodegenerative syndromes. This may lead to more precise patient management and sets a precedent for AI-driven neuroimaging diagnostics.
Source
Radiology Business
Related News
•Radiology Business
Epsilon Health Launches With $28M to Build 'AI-Native' Imaging Practice
Epsilon Health has exited stealth mode, raising nearly $28M to launch an 'AI-native' radiology imaging group aimed at addressing the U.S. radiologist shortage.
•Radiology Business
Harrison.ai Restructures and Launches U.S. AI-Enabled Teleradiology Venture
Harrison.ai lays off staff amid major restructuring and launches Frontier Radiology, an AI-powered U.S. teleradiology business.
•Radiology Business
AI Model Surpasses Radiologists in Detecting Subtle Hip Fractures
A new AI model outperformed radiologists in identifying difficult-to-detect femoral neck fractures on radiographs.